OMER Stock Tests Key Support After Second European Rejection For Narsoplimab
European regulators rejected Omeros’ application for Narsoplimab, which is used to treat hematopoietic stem cell transplant-associated thrombotic micr…
#Europe #EU #EMAlatest #European #EuropeanMedicinesAgencynews #Hematopoieticstemcelltransplant-associatedthromboticmicroangiopathy #Narsoplimabnews #OMERstock #Omeros #TA-TMA #USbiotechstocks #USlaggardstoday #USpre-marketlosers
https://www.europesays.com/europe/160525/